InvestorsHub Logo
icon url

GOLD DIGGAA

04/13/15 10:55 PM

#3760 RE: Paulness #3759

"The Sublicense Agreement grants patent rights to us on the same terms as such rights have been granted to Nanobeak under the License Agreement; provided, however, that the field of use for the patent rights granted to us is limited to disease detection."


Since they are just getting started out, I'm sure they will be more than welcome to procure a licensing agreement with Cannabix's technology.
icon url

coin8300

04/14/15 9:02 AM

#3763 RE: Paulness #3759

Vantage is not serious about narcotics detection at this point; they are focused on lung cancer. By the time/if they actually focus on developing their device for the needs of everyday use with law and enforcement and commercial applications, the Cannabix product will already be out. Not to mention that the Cannabix product is hands down better for law enforcement and commercial applications due to all the specific features the team is putting into the device that they know it will need to hold up in court, be robust, cost effective, etc...Vantage is interesting but in my opinion Cannabix is still the way to go if you are interested in investing in the first commercially successful marijuana breathalyzer product. Also, the Vantage products dependence on software that would be tied to a police officers personal device has never been tested in the court of law and I would be skeptical if that would fly. That means it would need a dedicated device acting in tandem with the unit which would be extremely expensive.